Building Biotech: Being ready for AI
Posted on 02 Feb 2026
AI is advancing faster than biotech's development, manufacturing, and regulatory frameworks were designed to support. In a recent Bioprocess Online column, our Managing Partners Lee Smith and Andrew M. Thomson explore what it will take for biotech to effectively integrate AI at the pace innovation now takes place.
Key insights from the article include:
- Why AI-driven discovery is outpacing downstream readiness in biotech
- When having biological, CMC and process validation alongside AI models is important
- What risks investors and leadership teams should assess beyond algorithmic performance
- How cross-functional expertise enables AI insights to translate into real world impact
View more blog posts
01
Live Attenuated Viral Vaccines Advancements
Innovation is continually taking place for a generation of new vaccines to meet patient needs across the globe.
02
Hope for Chlamydia STI Vaccine After Promising Initial Results
A vaccine to protect against Chlamydia has taken a step closer to licensure after successful phase 1 clinical trials.
03
Gene Therapy for Rare Disorders
Of the many medical breakthroughs over the past three decades, few have been as promising as gene therapy.
04
CEPI awards up to US$21 million to Themis Bioscience for Phase 3 Chikungunya Vaccine Development
CEPI awards US$21 million to Themis Bioscience.
05
GreyRigge Associates partners with NG Bio to accelerate VC investment
NG Bio and GreyRigge Associates Announce Strategic Partnership to Advance Biotech Innovation
06
Greyrigge Associates partner with SciPot Consultancy
GreyRigge Associates partner with Pharma and Biotech consultancy: SciPot Consultancy
07
Building Biotech: Being ready for AI
AI is advancing faster than biotech's frameworks were designed to support. In a recent Bioprocess Online column, our Managing Partners Lee and Andrew have documented what they think it will take for biotech to effectively integrate AI at the pace innovation now takes place.